BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565-1575. [PMID: 26364546 DOI: 10.1016/s0140-6736(15)00154-3] [Cited by in Crossref: 277] [Cited by in F6Publishing: 121] [Article Influence: 39.6] [Reference Citation Analysis]
Number Citing Articles
1 Yan X, Jin J. Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report. Medicine (Baltimore) 2018;97:e0004. [PMID: 29465536 DOI: 10.1097/MD.0000000000010004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Yoshida EM, Mason A, Peltekian KM, Shah H, Thiele S, Borrelli R, Fischer A. Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. CMAJ Open 2018;6:E664-70. [PMID: 30578275 DOI: 10.9778/cmajo.20180029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, Yang A, Wang T. Circular RNAs in immune responses and immune diseases. Theranostics 2019;9:588-607. [PMID: 30809295 DOI: 10.7150/thno.29678] [Cited by in Crossref: 57] [Cited by in F6Publishing: 66] [Article Influence: 19.0] [Reference Citation Analysis]
4 Ullah K, Uddin S, Dogar AW, Jan ZU, Abbas SH. Primary biliary cirrhosis in early childhood - A rare case report. Int J Surg Case Rep 2021;85:106215. [PMID: 34298422 DOI: 10.1016/j.ijscr.2021.106215] [Reference Citation Analysis]
5 Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM. Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. Hepatol Commun 2019;3:356-64. [PMID: 30859148 DOI: 10.1002/hep4.1314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM. NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatol Commun. 2018;2:1037-1050. [PMID: 30202819 DOI: 10.1002/hep4.1209] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
7 Floreani A, Mangini C, Reig A, Franceschet I, Cazzagon N, Perini L, Caballería L, Cocchio S, Baldo V, Parés A. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. Am J Gastroenterol 2017;112:114-9. [PMID: 27779196 DOI: 10.1038/ajg.2016.479] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ai X, Yang X, Fu HY, Xu JM, Tang YM. Health-related quality of life questionnaires used in primary biliary cholangitis: a systematic review. Scand J Gastroenterol 2022;:1-7. [PMID: 35107052 DOI: 10.1080/00365521.2021.2010800] [Reference Citation Analysis]
9 Loaeza-Del Castillo AM, Gaytán-Santillán A, López-Tello A, Merit MV, Milke-García MDP, Flores-Rodríguez J, Alvirde-García U. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol 2019;18:879-82. [PMID: 31506216 DOI: 10.1016/j.aohep.2019.07.006] [Reference Citation Analysis]
10 Goubran M, Wang W, Indik S, Faschinger A, Wasilenko ST, Bintner J, Carpenter EJ, Zhang G, Nuin P, Macintyre G, Wong GK, Mason AL. Isolation of a Human Betaretrovirus from Patients with Primary Biliary Cholangitis. Viruses 2022;14:886. [DOI: 10.3390/v14050886] [Reference Citation Analysis]
11 Mulinacci G, Palermo A, Invernizzi P, Carbone M. Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs 2021;9:123-31. [DOI: 10.1080/21678707.2021.1927700] [Reference Citation Analysis]
12 Watt M, Spence JC, Tandon P. Development of a Theoretically Informed Web-Based Mind-Body Wellness Intervention for Patients With Primary Biliary Cholangitis: Formative Study. JMIR Form Res 2021;5:e29064. [PMID: 34623317 DOI: 10.2196/29064] [Reference Citation Analysis]
13 Greverath LM, Leicht E, Wald de Chamorro N, Wilde AB, Steinhagen LM, Lieb C, Schmelzle M, Chopra S, Shibolet O, Fischer J, Berg T, Tacke F, Müller T. Evaluation of muscarinic acetylcholine receptor type 3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Res 2020;50:321-9. [PMID: 31747477 DOI: 10.1111/hepr.13455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Kouroumalis E, Samonakis D, Voumvouraki A. Biomarkers for primary biliary cholangitis: current perspectives. Hepat Med 2018;10:43-53. [PMID: 29950909 DOI: 10.2147/HMER.S135337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang Y, Guo P, Zhang Y, Liu L, Yan R, Yuan Z, Song Y. Joint Analysis of Genetic Correlation, Mendelian Randomization and Colocalization Highlights the Bi-Directional Causal Association Between Hypothyroidism and Primary Biliary Cirrhosis. Front Genet 2021;12:753352. [PMID: 34671386 DOI: 10.3389/fgene.2021.753352] [Reference Citation Analysis]
16 Kato T, Akagawa S, Kusaka K, Kawashima M, Ohshima N, Kitani M, Hebisawa A, Matsui H. An autopsy case report of yellow nail syndrome coincided with primary biliary cholangitis. Respir Med Case Rep 2021;32:101332. [PMID: 33511030 DOI: 10.1016/j.rmcr.2020.101332] [Reference Citation Analysis]
17 Li L, Xu P, Zhou Q, Xu J. The Function of T Follicular Helper Cells in the Autoimmune Liver Diseases. J Immunol Res 2020;2020:5679254. [PMID: 33294464 DOI: 10.1155/2020/5679254] [Reference Citation Analysis]
18 Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, You H, Kong Y, Jia J. Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterol Res Pract. 2019;2019:8959103. [PMID: 31281353 DOI: 10.1155/2019/8959103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
20 Wang C, Zheng X, Jiang P, Tang R, Gong Y, Dai Y, Wang L, Xu P, Sun W, Wang L, Han C, Jiang Y, Wei Y, Zhang K, Wu J, Shao Y, Gao Y, Yu J, Hu Z, Zang Z, Zhao Y, Wu X, Dai N, Liu L, Nie J, Jiang B, Lin M, Li L, Li Y, Chen S, Shu L, Qiu F, Wu Q, Zhang M, Chen R, Jawed R, Zhang Y, Shi X, Zhu Z, Pei H, Huang L, Zhao W, Tian Y, Zhu X, Qiu H, Gershwin ME, Chen W, Seldin MF, Liu X, Sun L, Ma X. Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis. Hepatology 2019;70:294-307. [PMID: 30854688 DOI: 10.1002/hep.30604] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
21 Thoeni C, Waldherr R, Scheuerer J, Schmitteckert S, Roeth R, Niesler B, Cutz E, Flechtenmacher C, Goeppert B, Schirmacher P, Lasitschka F. Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases. Can J Gastroenterol Hepatol 2019;2019:1085717. [PMID: 31886153 DOI: 10.1155/2019/1085717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Cançado GGL, Braga MH, Ferraz MLG, Villela-Nogueira CA, Terrabuio DRB, Cançado ELR, Nardelli MJ, Faria LC, Gomes NMF, de Oliveira EMG, Rotman V, de Oliveira MB, da Cunha SMCF, Mazo DFC, Mendes LSC, Ivantes CAP, Codes L, de Almeida E Borges VF, Pace FHL, Pessoa MG, Signorelli IV, Coral GP, Bittencourt PL, Levy C, Couto CA; Members of the Brazilian Cholestasis Study Group Consortium. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Ann Hepatol 2021;27:100546. [PMID: 34600142 DOI: 10.1016/j.aohep.2021.100546] [Reference Citation Analysis]
23 Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW. A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. Hepatol Commun 2018;2:484-91. [PMID: 29761165 DOI: 10.1002/hep4.1173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Mané F, Cardoso H, Liberal R, Lopes S, Pereira P, Gonçalves R, Macedo G. Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features. Ann Hepatol 2019;18:488-93. [PMID: 31036497 DOI: 10.1016/j.aohep.2018.11.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ali AH, Tabibian JH, Lindor KD. Update on pharmacotherapies for cholestatic liver disease. Hepatol Commun 2017;1:7-17. [PMID: 29404429 DOI: 10.1002/hep4.1013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
26 Lu C, Hou X, Li M, Wang L, Zeng P, Jia H, Chen J, Wei Y, He H, Liu X, Diao H. Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis. Sci Rep 2017;7:796. [PMID: 28400582 DOI: 10.1038/s41598-017-00906-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018;67:1890-902. [PMID: 29023915 DOI: 10.1002/hep.29569] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 27.5] [Reference Citation Analysis]
28 Zhai X, Zhang Y, Xin S, Cao P, Lu J. Insights Into the Involvement of Circular RNAs in Autoimmune Diseases. Front Immunol 2021;12:622316. [PMID: 33717126 DOI: 10.3389/fimmu.2021.622316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wong KA, Bahar R, Liu CH, Bowlus CL. Current Treatment Options for Primary Biliary Cholangitis. Clin Liver Dis 2018;22:481-500. [PMID: 30259848 DOI: 10.1016/j.cld.2018.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Dai Z, Song G, Balakrishnan A, Yang T, Yuan Q, Möbus S, Weiss AC, Bentler M, Zhu J, Jiang X, Shen X, Bantel H, Jaeckel E, Kispert A, Vogel A, Saborowski A, Büning H, Manns M, Cantz T, Ott M, Sharma AD. Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells. Gut 2020;69:1104-15. [PMID: 31767630 DOI: 10.1136/gutjnl-2019-318812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
31 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
32 D'Amato D, De Vincentis A, Malinverno F, Viganò M, Alvaro D, Pompili M, Picciotto A, Palitti VP, Russello M, Storato S, Pigozzi MG, Calvaruso V, De Gasperi E, Lleo A, Castellaneta A, Pellicelli A, Cazzagon N, Floreani A, Muratori L, Fagiuoli S, Niro GA, Feletti V, Cozzolongo R, Terreni N, Marzioni M, Pellicano R, Pozzoni P, Baiocchi L, Chessa L, Rosina F, Bertino G, Vinci M, Morgando A, Vanni E, Scifo G, Sacco R, D'Antò M, Bellia V, Boldizzoni R, Casella S, Omazzi B, Poggi G, Cristoferi L, Gerussi A, Ronca V, Venere R, Ponziani F, Cannavò M, Mussetto A, Fontana R, Losito F, Frazzetto E, Distefano M, Colapietro F, Labanca S, Marconi G, Grassi G, Galati G, O'Donnell SE, Mancuso C, Mulinacci G, Palermo A, Claar E, Izzi A, Picardi A, Invernizzi P, Carbone M, Vespasiani-Gentilucci U; Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep 2021;3:100248. [PMID: 33681748 DOI: 10.1016/j.jhepr.2021.100248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
34 Nguyen HH, Khathlan A, Fritzler MJ, Swain MG. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. BMC Gastroenterol 2018;18:97. [PMID: 29940867 DOI: 10.1186/s12876-018-0826-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Jhaveri MA, Kowdley KV. New developments in the treatment of primary biliary cholangitis - role of obeticholic acid. Ther Clin Risk Manag 2017;13:1053-60. [PMID: 28860789 DOI: 10.2147/TCRM.S113052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Al-Dury S, Wahlström A, Wahlin S, Langedijk J, Elferink RO, Ståhlman M, Marschall HU. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep 2018;8:6658. [PMID: 29704003 DOI: 10.1038/s41598-018-25214-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
37 Petrie E, Hoppmann NA, Wilcox CM, Al Diffalha S, Gray ME. Gastric Xanthomatosis Secondary to Lipoprotein X in Primary Biliary Cholangitis. J Investig Med High Impact Case Rep 2022;10:23247096221089488. [PMID: 35403472 DOI: 10.1177/23247096221089488] [Reference Citation Analysis]
38 Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J 2020;8:667-74. [PMID: 32299307 DOI: 10.1177/2050640620919585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, Del Pozo V. Emerging Evidence for Pleiotropism of Eosinophils. Int J Mol Sci 2021;22:7075. [PMID: 34209213 DOI: 10.3390/ijms22137075] [Reference Citation Analysis]
40 Floreani A. Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis. J Exp Pharmacol 2020;12:643-52. [PMID: 33364858 DOI: 10.2147/JEP.S267375] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Wan YD, Zhu RX, Pan XT, Sun TW. Bile Acid Supplementation Improves Murine Pancreatitis in Association With the Gut Microbiota. Front Physiol 2020;11:650. [PMID: 32612539 DOI: 10.3389/fphys.2020.00650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Zhou X, Yu R, Long Y, Zhao J, Yu S, Tang Q, Chen L. BMAL1 deficiency promotes skeletal mandibular hypoplasia via OPG downregulation. Cell Prolif 2018;51:e12470. [PMID: 30117209 DOI: 10.1111/cpr.12470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
43 Marschall HU, Henriksson I, Lindberg S, Söderdahl F, Thuresson M, Wahlin S, Ludvigsson JF. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep 2019;9:11525. [PMID: 31395896 DOI: 10.1038/s41598-019-47890-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
44 Heijke R, Ahmad A, Frodlund M, Wirestam L, Dahlström Ö, Dahle C, Kechagias S, Sjöwall C. Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. J Clin Med 2021;10:3820. [PMID: 34501268 DOI: 10.3390/jcm10173820] [Reference Citation Analysis]
45 Hallett JM, Ferreira-Gonzalez S, Man TY, Kilpatrick AM, Esser H, Thirlwell K, Macmillan MT, Rodrigo-Torres D, Dwyer BJ, Gadd VL, Ashmore-Harris C, Lu WY, Thomson JP, Jansen MA, O'Duibhir E, Starkey Lewis PJ, Campana L, Aird RE, Bate TSR, Fraser AR, Campbell JDM, Oniscu GC, Hay DC, Callanan A, Forbes SJ. Human biliary epithelial cells from discarded donor livers rescue bile duct structure and function in a mouse model of biliary disease. Cell Stem Cell 2022;29:355-371.e10. [PMID: 35245467 DOI: 10.1016/j.stem.2022.02.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Li J, Lu M, Zhou Y, Bowlus CL, Lindor K, Rodriguez-Watson C, Romanelli RJ, Haller IV, Anderson H, VanWormer JJ, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Wu KH, Trudeau S, Rupp LB, Melkonian C, Gordon SC; FOLD Investigators. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. Dig Dis Sci 2021. [PMID: 34499271 DOI: 10.1007/s10620-021-07219-4] [Reference Citation Analysis]
47 Abenavoli L, Procopio AC, Fagoonee S, Pellicano R, Carbone M, Luzza F, Invernizzi P. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases 2020;8:E20. [PMID: 32532037 DOI: 10.3390/diseases8020020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Fan X, Wang T, Shen Y, Xi X, Yang L. Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients. Sci Rep 2017;7:6560. [PMID: 28747696 DOI: 10.1038/s41598-017-06807-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
49 Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. World J Gastroenterol 2017; 23(44): 7863-7874 [PMID: 29209127 DOI: 10.3748/wjg.v23.i44.7863] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int 2021;41:1335-43. [PMID: 33751787 DOI: 10.1111/liv.14871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021; 13(12): 1956-1967 [DOI: 10.4254/wjh.v13.i12.1956] [Reference Citation Analysis]
52 Bauer A, Habior A. Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis. Ann Lab Med 2019;39:291-8. [PMID: 30623621 DOI: 10.3343/alm.2019.39.3.291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
53 Parast L, Rutter CM. Discussion of "A risk-based measure of time-varying prognostic discrimination for survival models," by C. Jason Liang and Patrick J. Heagerty. Biometrics 2017;73:742-4. [PMID: 27933633 DOI: 10.1111/biom.12630] [Reference Citation Analysis]
54 Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol 2017;10:791-803. [PMID: 29051789 DOI: 10.1177/1756283X17728669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci. 2020;21:5097. [PMID: 32707678 DOI: 10.1038/s41575-019-0226-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
56 Li X, Liu X, Cui J, Song W, Liang Y, Hu Y, Guo Y. Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. J Clin Lab Anal 2019;33:e22965. [PMID: 31313384 DOI: 10.1002/jcla.22965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Tan S, Movahedi Z, Beisel J, Ayutyanont N, Nadir A. Correlation of Anti-mitochondrial Antibodies with Liver Histology and Outcomes. Dig Dis Sci 2016;61:1770-1. [PMID: 26972083 DOI: 10.1007/s10620-016-4094-5] [Reference Citation Analysis]
58 Kong Y, Li M, Wu X, Xia C, Liu X, Wang G. Protective mechanism of homologous lactic acid bacteria against cholestatic liver injury in snakehead fish. Aquaculture 2022;550:737845. [DOI: 10.1016/j.aquaculture.2021.737845] [Reference Citation Analysis]
59 Wang Y, Li Y, Wang X, Gacesa R, Zhang J, Zhou L, Wang B. Predicting Liver Disease Risk Using a Combination of Common Clinical Markers: A Screening Model from Routine Health Check-Up. Dis Markers 2020;2020:8460883. [PMID: 32566041 DOI: 10.1155/2020/8460883] [Reference Citation Analysis]
60 Liu SP, Bian ZH, Zhao ZB, Wang J, Zhang W, Leung PSC, Li L, Lian ZX. Animal Models of Autoimmune Liver Diseases: a Comprehensive Review. Clin Rev Allergy Immunol 2020;58:252-71. [PMID: 32076943 DOI: 10.1007/s12016-020-08778-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Zhang H, Liu Y, Li Z, Liang N, Zhou X, Nie X, Zhang T, Qi W. Amyotrophic Lateral Sclerosis and Primary Biliary Cirrhosis Overlap Syndrome: Two Cases Report. Front Neurol 2019;10:890. [PMID: 31474934 DOI: 10.3389/fneur.2019.00890] [Reference Citation Analysis]
62 Cortez-Pinto H, Liberal R, Lopes S, Machado MV, Carvalho J, Dias T, Santos A, Agostinho C, Figueiredo P, Loureiro R, Martins A, Alexandrino G, Cotrim I, Leal C, Presa J, Mesquita M, Nunes J, Gouveia C, Vale AHE, Alves AL, Coelho M, Maia L, Pedroto I, Banhudo A, Pinto JS, Gomes MV, Oliveira J, Andreozzi V, Calinas F. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J 2021;9:699-706. [PMID: 34102008 DOI: 10.1002/ueg2.12095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Wasik U, Wunsch E, Norman GL, Rigopoulou EI, Bogdanos DP, Milkiewicz P, Milkiewicz M. Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. J Immunol Res 2017;2017:2185083. [PMID: 28299343 DOI: 10.1155/2017/2185083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Bauer A, Habior A. Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis. Front Immunol 2022;13:885229. [DOI: 10.3389/fimmu.2022.885229] [Reference Citation Analysis]
65 Koo JH, Han CY. Signaling Nodes Associated with Endoplasmic Reticulum Stress during NAFLD Progression. Biomolecules 2021;11:242. [PMID: 33567666 DOI: 10.3390/biom11020242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Chen W, Wei Y, Xiong A, Li Y, Guan H, Wang Q, Miao Q, Bian Z, Xiao X, Lian M, Zhang J, Li B, Cao Q, Fan Z, Zhang W, Qiu D, Fang J, Gershwin ME, Yang L, Tang R, Ma X. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.Clin Rev Allergy Immunol. 2020;58:25-38. [PMID: 30900136 DOI: 10.1007/s12016-019-08731-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
67 Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Semin Liver Dis 2019;39:422-31. [PMID: 31226726 DOI: 10.1055/s-0039-1688751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
68 Wan M, Ding L, Wang D, Han J, Gao P. Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases. Front Immunol 2020;11:186. [PMID: 32117308 DOI: 10.3389/fimmu.2020.00186] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
69 Harms MH, Janssen QP, Adam R, Duvoux C, Mirza D, Hidalgo E, Watson C, Wigmore SJ, Pinzani M, Isoniemi H, Pratschke J, Zieniewicz K, Klempnauer JL, Bennet W, Karam V, van Buuren HR, Hansen BE, Metselaar HJ; European Liver and Intestine Transplant Association (ELITA). Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther 2019;49:285-95. [PMID: 30561112 DOI: 10.1111/apt.15060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
70 Molinaro A, Marschall HU. Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications? Curr Hepatol Rep 2017;16:119-23. [PMID: 28706773 DOI: 10.1007/s11901-017-0345-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
71 Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T, Song Q, Zhu F, Zhang L, Jiang M, Zhou Y, Barve S, Zhang X, McClain CJ, Feng W. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. Hepatology. 2020;71:2050-2066. [PMID: 31571251 DOI: 10.1002/hep.30975] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
72 Cazzagon N, Dal Lin C, Famoso G, Montisci R, Franceschet I, Floreani A, Tona F. Coronary flow reserve in patients with primary biliary cholangitis. Dig Liver Dis 2019;51:542-8. [PMID: 30448459 DOI: 10.1016/j.dld.2018.10.016] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 McDaniel K, Hall C, Sato K, Lairmore T, Marzioni M, Glaser S, Meng F, Alpini G. Lin28 and let-7: roles and regulation in liver diseases. Am J Physiol Gastrointest Liver Physiol 2016;310:G757-65. [PMID: 27012771 DOI: 10.1152/ajpgi.00080.2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
74 Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, Yang L. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2021;2021:6691425. [PMID: 33542908 DOI: 10.1155/2021/6691425] [Reference Citation Analysis]
75 Zhang D, Men H, Zhang L, Gao X, Wang J, Li L, Zhu Q, Zhang H, Jia Z. Inhibition of M/Kv7 Currents Contributes to Chloroquine-Induced Itch in Mice. Front Mol Neurosci 2020;13:105. [PMID: 32694980 DOI: 10.3389/fnmol.2020.00105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, Theriot CM. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids. Infect Immun 2020;88:e00045-20. [PMID: 32205405 DOI: 10.1128/IAI.00045-20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
77 Lin CY, Cheng YT, Chang ML, Chien RN. The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study. Sci Rep 2019;9:7577. [PMID: 31110209 DOI: 10.1038/s41598-019-44081-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, Cataldo I, Covelli C, Mangia A, Guido M. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica 2021;113:170-84. [PMID: 34294935 DOI: 10.32074/1591-951X-245] [Reference Citation Analysis]
79 Fan J, Wang Q, Sun L. Association between primary biliary cholangitis and osteoporosis: meta-analysis. Clin Rheumatol 2017;36:2565-71. [PMID: 28948408 DOI: 10.1007/s10067-017-3844-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
80 Zeng X, Li S, Tang S, Li X, Zhang G, Li M, Zeng X, Hu C. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. Front Immunol 2021;12:669137. [PMID: 34248947 DOI: 10.3389/fimmu.2021.669137] [Reference Citation Analysis]
81 Zhao Q, Liu F, Cheng Y, Xiao XR, Hu DD, Tang YM, Bao WM, Yang JH, Jiang T, Hu JP, Gonzalez FJ, Li F. Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling. Mol Cell Proteomics 2019;18:520-33. [PMID: 30617157 DOI: 10.1074/mcp.RA118.000817] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
82 Reig A, Sesé P, Parés A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol 2018;113:49-55. [PMID: 29016567 DOI: 10.1038/ajg.2017.287] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
83 Horst AK, Kumashie KG, Neumann K, Diehl L, Tiegs G. Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease. Cell Mol Immunol 2021;18:92-111. [PMID: 33110250 DOI: 10.1038/s41423-020-00568-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
84 Tanaka A, Leung PSC, Young HA, Gershwin ME. Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. Arch Med Sci 2018;14:930-40. [PMID: 30002712 DOI: 10.5114/aoms.2017.70995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Seth RK, Kimono D, Alhasson F, Sarkar S, Albadrani M, Lasley SK, Horner R, Janulewicz P, Nagarkatti M, Nagarkatti P, Sullivan K, Chatterjee S. Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness. Toxicol Appl Pharmacol 2018;350:64-77. [PMID: 29751049 DOI: 10.1016/j.taap.2018.05.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
86 Liu HM, Zhang HW, Lin R, Song Y, Zhou L, Wang BM, Liu WT. Clinical features of patients with refractory primary biliary cholangitis. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 238-244 [DOI: 10.11569/wcjd.v27.i4.238] [Reference Citation Analysis]
87 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
88 Sun Q, Wang Q, Feng N, Meng Y, Li B, Luo D, Shang X, Lv J, Monsaf AM, Wang C, Ma X. The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis. Ann Transl Med 2019;7:389. [PMID: 31555703 DOI: 10.21037/atm.2019.07.100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Kern C, Elmoursi A, Blake C, Hoellein A. Syphilis Hepatitis Presenting as a Mimic of Primary Biliary Cholangitis. ACG Case Rep J 2020;7:e00497. [PMID: 33324716 DOI: 10.14309/crj.0000000000000497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Tanaka A, Leung PS, Gershwin ME. Environmental basis of primary biliary cholangitis. Exp Biol Med (Maywood) 2018;243:184-9. [PMID: 29307284 DOI: 10.1177/1535370217748893] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
91 Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun 2018;2:821-35. [PMID: 30027140 DOI: 10.1002/hep4.1193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
92 Chalifoux SL, Konyn PG, Choi G, Saab S. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver 2017;11:771-80. [PMID: 28292174 DOI: 10.5009/gnl16365] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
93 Zhang HC, Hu RF, Zhu T, Tong L, Zhang QQ. Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators. World J Gastroenterol 2016; 22(22): 5276-5284 [PMID: 27298571 DOI: 10.3748/wjg.v22.i22.5276] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
94 Tanaka A, Takikawa H, Mochida S, Koike K, Miwa H, Shimosegawa T. Changing Nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis". J Gastroenterol 2016;51:748-9. [PMID: 27230619 DOI: 10.1007/s00535-016-1223-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Han Y, Bian Z, Yang S, Wang C, Li L, Yang Y, Ansari AA, Gershwin ME, Zeng X, Lian Z, Zhao Z. Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis. Front Immunol 2022;13:860311. [DOI: 10.3389/fimmu.2022.860311] [Reference Citation Analysis]
96 Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PLoS One. 2017;12:e0186643. [PMID: 29049401 DOI: 10.1371/journal.pone.0186643] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
97 Adam L, Zoldan K, Hofmann M, Schultheiss M, Bettinger D, Neumann-Haefelin C, Thimme R, Böettler T. Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatol Commun 2018;2:1051-63. [PMID: 30202820 DOI: 10.1002/hep4.1226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
98 Leung PS, Choi J, Yang G, Woo E, Kenny TP, Gershwin ME. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn 2016;16:697-705. [PMID: 26953925 DOI: 10.1586/14737159.2016.1164038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
99 Wang Z, Peng C, Wang P, Sui J, Wang Y, Sun G, Liu M. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol 2020;55:1333-40. [PMID: 33021858 DOI: 10.1080/00365521.2020.1829030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Diny NL, Rose NR, Čiháková D. Eosinophils in Autoimmune Diseases. Front Immunol 2017;8:484. [PMID: 28496445 DOI: 10.3389/fimmu.2017.00484] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 13.4] [Reference Citation Analysis]
101 Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.Br J Pharmacol. 2018;175:469-484. [PMID: 29139555 DOI: 10.1111/bph.14095] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
102 Liu Z, Zhang Z, Huang M, Sun X, Liu B, Guo Q, Chang Q, Duan Z. Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments. BMC Gastroenterol 2018;18:112. [PMID: 29996772 DOI: 10.1186/s12876-018-0842-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
103 Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, Dalekos GN, Renaudineau Y. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. Epigenomes 2019;3:15. [PMID: 34968227 DOI: 10.3390/epigenomes3030015] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
104 Zhao Y, Yin Z, Du H, Huang K, Zhang F, Chen H. The latest research trends in primary biliary cholangitis: a bibliometric analysis. Clin Exp Med 2022. [PMID: 35389157 DOI: 10.1007/s10238-022-00825-0] [Reference Citation Analysis]
105 Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clin Transl Gastroenterol. 2017;8:e100. [PMID: 28640288 DOI: 10.1038/ctg.2017.23] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
106 Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One 2021;16:e0246161. [PMID: 33600468 DOI: 10.1371/journal.pone.0246161] [Reference Citation Analysis]
107 Li J, Yu D, Chen S, Liu Y, Shi J, Zhang J, Wen P, Wang Z, Li J, Guo W, Zhang S. Sirt6 opposes glycochenodeoxycholate-induced apoptosis of biliary epithelial cells through the AMPK/PGC-1α pathway. Cell Biosci 2020;10:43. [PMID: 32206298 DOI: 10.1186/s13578-020-00402-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116. [PMID: 28858291 DOI: 10.1038/ctg.2017.43] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
109 Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology 2016;64:2151-64. [PMID: 27639250 DOI: 10.1002/hep.28826] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
110 Parés A. Advances in treatment options for patients with primary biliary cholangitis. Expert Opinion on Orphan Drugs 2017;5:847-57. [DOI: 10.1080/21678707.2017.1394840] [Reference Citation Analysis]
111 Deng CW, Wang L, Fei YY, Hu CJ, Yang YJ, Peng LY, Zeng XF, Zhang FC, Li YZ. Exploring pathogenesis of primary biliary cholangitis by proteomics: A pilot study. World J Gastroenterol 2017; 23(48): 8489-8499 [PMID: 29358857 DOI: 10.3748/wjg.v23.i48.8489] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
112 Ainosah RH, Hagras MM, Alharthi SE, Saadah OI. The effects of ursodeoxycholic acid on sepsis-induced cholestasis management in an animal model. J Taibah Univ Med Sci 2020;15:312-20. [PMID: 32982635 DOI: 10.1016/j.jtumed.2020.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Alfano AM, Romito A, Marchese C, Battistini M, Crotti G, Ferrini A, Mancinetti C, Manetta T, Mengozzi G, Merlach P, Migliardi M, Tambuzzo MT. Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? Immunol Res 2017;65:299-306. [PMID: 27475095 DOI: 10.1007/s12026-016-8838-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Zeng N, Duan W, Chen S, Wu S, Ma H, Ou X, You H, Kong Y, Jia J. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int 2019;13:788-99. [PMID: 31552558 DOI: 10.1007/s12072-019-09984-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
115 Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. J Clin Transl Hepatol 2020;8:49-60. [PMID: 32274345 DOI: 10.14218/JCTH.2019.00049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
116 Tian S, Liu Y, Sun K, Zhou X, Ma S, Zhang M, Zhou X, Wang L, Han Y. A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis. J Clin Lab Anal 2020;34:e23501. [PMID: 32915500 DOI: 10.1002/jcla.23501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Huang P, Hou Y, Zou Y, Ye X, Yu R, Yang S. The Causal Effects of Primary Biliary Cholangitis on Thyroid Dysfunction: A Two-Sample Mendelian Randomization Study. Front Genet 2021;12:791778. [PMID: 34956333 DOI: 10.3389/fgene.2021.791778] [Reference Citation Analysis]
118 Xie AJ, Mai CT, Zhu YZ, Liu XC, Xie Y. Bile acids as regulatory molecules and potential targets in metabolic diseases. Life Sci 2021;287:120152. [PMID: 34793769 DOI: 10.1016/j.lfs.2021.120152] [Reference Citation Analysis]
119 Tang Y, Blomenkamp KS, Fickert P, Trauner M, Teckman JH. NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. PLoS One 2018;13:e0200897. [PMID: 30067827 DOI: 10.1371/journal.pone.0200897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
120 Ahmad A, Heijke R, Eriksson P, Wirestam L, Kechagias S, Dahle C, Sjöwall C. Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. Clin Exp Immunol 2021;203:22-31. [PMID: 32910463 DOI: 10.1111/cei.13512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Yoshida EM, Swain MG, Tsien C, Tam E, Bailey RJ, Grbic D, Hin Ko H, Ramji A, Hilzenrat N, Elkhashab M, Kim E, O'brien M, Amedeo Puglia M, Peltekian KM. Clinical characterization of patients with primary biliary cholangitis: A report from multiple Canadian centres. CanLivJ. [DOI: 10.3138/canlivj-2021-0038] [Reference Citation Analysis]
122 Wilde AB, Lieb C, Leicht E, Greverath LM, Steinhagen LM, Wald de Chamorro N, Petersen J, Hofmann WP, Hinrichsen H, Heyne R, Berg T, Naumann U, Schwenzer J, Vermehren J, Geier A, Tacke F, Müller T. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany. J Clin Med 2021;10:1061. [PMID: 33806503 DOI: 10.3390/jcm10051061] [Reference Citation Analysis]
123 Terziroli Beretta-Piccoli B, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Kalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clin Rev Allergy Immunol 2018;54:295-306. [PMID: 29181702 DOI: 10.1007/s12016-017-8656-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
124 Bauer A, Habior A, Gawel D. Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis. Biomedicines 2022;10:801. [DOI: 10.3390/biomedicines10040801] [Reference Citation Analysis]
125 Bhatt D, Stan RC, Pinhata R, Machado M, Maity S, Cunningham-Rundles C, Vogel C, de Camargo MM. Chemical chaperones reverse early suppression of regulatory circuits during unfolded protein response in B cells from common variable immunodeficiency patients. Clin Exp Immunol 2020;200:73-86. [PMID: 31859362 DOI: 10.1111/cei.13410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Wang H, Xu H, Wang X, Wu R, Gao X, Jin Q, Niu J. Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. Medicine (Baltimore) 2016;95:e3114. [PMID: 26986159 DOI: 10.1097/MD.0000000000003114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
127 Labanca S, Cacciato V, Borro P, Marenco S, Pieri G, Picciotto A, Plaz Torres MC, Giannini EG. Obeticholic Acid Improves Aminotransferases Early during Treatment in Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid: A Study in Clinical Practice. Immuno 2021;1:457-67. [DOI: 10.3390/immuno1040033] [Reference Citation Analysis]
128 Hartmann P, Chu H, Duan Y, Schnabl B. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol 2019;316:G563-73. [PMID: 30767680 DOI: 10.1152/ajpgi.00370.2018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
129 She C, Wang J, Tang N, Liu Z, Xu L, Liu B. Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on T Cell Differentiation in Primary Biliary Cholangitis. Biomed Res Int 2020;2020:1754975. [PMID: 32908870 DOI: 10.1155/2020/1754975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci 2020;21:E5097. [PMID: 32707678 DOI: 10.3390/ijms21145097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
131 Madir A, Božin T, Mikolašević I, Milić S, Štimac D, Mijić M, Filipec Kanižaj T, Biloglav Z, Lucijanić M, Lucijanić I, Grgurević I. Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study. Croat Med J 2019;60:494-502. [PMID: 31894914 [PMID: 31894914 DOI: 10.3325/cmj.2019.60.494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
132 Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, Li Y, Zhang F. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study. PLoS One 2018;13:e0194397. [PMID: 29543892 DOI: 10.1371/journal.pone.0194397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 2020;11:158-171. [PMID: 31595814 DOI: 10.1080/19490976.2019.1674124] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
134 Nicoli ER, Al Eisa N, Cluzeau CV, Wassif CA, Gray J, Burkert KR, Smith DA, Morris L, Cologna SM, Peer CJ, Sissung TM, Uscatu CD, Figg WD, Pavan WJ, Vite CH, Porter FD, Platt FM. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. PLoS One 2016;11:e0152007. [PMID: 27019000 DOI: 10.1371/journal.pone.0152007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
135 Gao L, Zhang Y, Gao X, Xu L, Duan X. Methylation of the HCBP6 promoter is associated with primary biliary cholangitis pathogenesis. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.03.080] [Reference Citation Analysis]
136 Qin Y, Yin G, Xie QB. Severe anemia caused by hereditary hemorrhagic telangiectasia in a patient with Sjögren's syndrome and primary biliary cirrhosis. Chin Med J (Engl) 2019;132:2382-3. [PMID: 31503060 DOI: 10.1097/CM9.0000000000000434] [Reference Citation Analysis]
137 Thomsen H, Li X, Sundquist K, Sundquist J, Försti A, Hemminki K. Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases. PLoS One 2020;15:e0240794. [PMID: 33079961 DOI: 10.1371/journal.pone.0240794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med 2021;9:441. [PMID: 33842662 DOI: 10.21037/atm-20-4894] [Reference Citation Analysis]
139 Ma JL, He LL, Li P, Jiang Y, Hu JL, Zhou YL, Liang XX, Wei HS. Clinical Features and Outcomes of Repeated Endoscopic Therapy for Esophagogastric Variceal Hemorrhage in Cirrhotic Patients: Ten-Year Real-World Analysis. Gastroenterol Res Pract 2020;2020:5747563. [PMID: 32508912 DOI: 10.1155/2020/5747563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Umemura T, Joshita S, Yamazaki T, Komatsu M, Katsuyama Y, Yoshizawa K, Tanaka E, Ota M. Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. Sci Rep 2016;6:29770. [PMID: 27406031 DOI: 10.1038/srep29770] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
141 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers - 18 (2016). J Clin Exp Hepatol 2016;6:159-63. [PMID: 27493465 DOI: 10.1016/j.jceh.2016.06.174] [Reference Citation Analysis]
142 Wang MN, Yu HT, Li YQ, Zeng Y, Yang S, Yang GP, Pei Q, Huang J. Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions. Drug Des Devel Ther 2021;15:185-93. [PMID: 33469270 DOI: 10.2147/DDDT.S289016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 2020;69:1502-9. [PMID: 31843787 DOI: 10.1136/gutjnl-2019-319057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
144 Fan X, Wen M, Shen Y, Wang W, Yang X, Yang L. Does adding variceal status to the Child-Turcotte-Pugh score improve its performance in predicting mortality in cirrhosis? Medicine (Baltimore) 2016;95:e4884. [PMID: 27661030 DOI: 10.1097/MD.0000000000004884] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
145 Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, Nakajima A. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs 2021;81:1181-92. [PMID: 34142342 DOI: 10.1007/s40265-021-01545-7] [Reference Citation Analysis]
146 Huang YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol 2016; 8(33): 1419-1441 [PMID: 27957241 DOI: 10.4254/wjh.v8.i33.1419] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
147 Sayiner M, Stepanova M, De Avila L, Golabi P, Racila A, Younossi ZM. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Dig Dis Sci 2020;65:416-22. [PMID: 31451982 DOI: 10.1007/s10620-019-05786-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
148 Zhang H, Xu H, Zhang C, Tang Q, Bi F. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov 2021;7:207. [PMID: 34365464 DOI: 10.1038/s41420-021-00589-8] [Reference Citation Analysis]
149 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
150 Ali AH, Carey EJ, Lindor KD. Targets and investigative treatments for primary biliary cholangitis. Expert Opinion on Orphan Drugs 2016;4:1011-20. [DOI: 10.1080/21678707.2016.1227240] [Reference Citation Analysis]
151 Patel A, Seetharam A. Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. J Clin Exp Hepatol. 2016;6:311-318. [PMID: 28003721 DOI: 10.1016/j.jceh.2016.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
152 Manno V, Gerussi A, Carbone M, Minelli G, Taruscio D, Conti S, Invernizzi P. A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis. Hepatol Commun 2019;3:1250-7. [PMID: 31497745 DOI: 10.1002/hep4.1407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
153 Chen Z, Liu S, He C, Sun J, Wang L, Chen H, Zhang F. CXCL12-CXCR4-Mediated Chemotaxis Supports Accumulation of Mucosal-Associated Invariant T Cells Into the Liver of Patients With PBC. Front Immunol 2021;12:578548. [PMID: 33815355 DOI: 10.3389/fimmu.2021.578548] [Reference Citation Analysis]
154 Hao J, Yang T, Zhou Y, Gao GY, Xing F, Peng Y, Tao YY, Liu CH. Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis. Sci Rep 2017;7:784. [PMID: 28400566 DOI: 10.1038/s41598-017-00944-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
155 Talebian R, Panahipour L, Gruber R. Ursodeoxycholic acid attenuates the expression of proinflammatory cytokines in periodontal cells. J Periodontol 2020. [PMID: 31960968 DOI: 10.1002/JPER.19-0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
156 Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol 2019;6:e000256. [PMID: 30815273 DOI: 10.1136/bmjgast-2018-000256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
157 Liu Y, Wang J, Luo S, Zhan Y, Lu Q. The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review. J Autoimmun 2020;113:102510. [PMID: 32622513 DOI: 10.1016/j.jaut.2020.102510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
158 Lin L, Piao M, Jiang X, Lv H, Zhao N, Yang F, Sun C. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort. BMJ Open. 2017;7:e015304. [PMID: 28706093 DOI: 10.1136/bmjopen-2016-015304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
159 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Reference Citation Analysis]
160 Im C, Sapkota Y, Moon W, Kawashima M, Nakamura M, Tokunaga K, Yasui Y. Genome-wide haplotype association analysis of primary biliary cholangitis risk in Japanese. Sci Rep 2018;8:7806. [PMID: 29773854 DOI: 10.1038/s41598-018-26112-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
161 Feng L, Dong K, Zhang X, Ma B, Chen L, Yang Q, Chen Q, Wen X, Jin Q. Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China. PLoS One 2020;15:e0242164. [PMID: 33180817 DOI: 10.1371/journal.pone.0242164] [Reference Citation Analysis]